Figure 1: Resveratrol, but not rapamycin, mitigates HFD-induced obesity.

(A) Effects of resveratrol or rapamycin treatment on temporal changes in the body weight (BW) of NCD- or HFD-fed mice over 8 weeks. (B) BW, (C) adiposity index (AI), and (D) epididymal fat pad weight measured after 8 weeks of resveratrol or rapamycin treatment (E) Food intake (FI) by the resveratrol- or rapamycin-treated groups. Data are expressed as the mean ± SEM (n = 5 per group). F- and p-values are from two-way ANOVA after Bonferroni’s post hoc test. *P < 0.05, **P < 0.005.